Biodesix Inc BDSX
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-28 |
| Shares Out. | 10,360,000 |
| Website | biodesix.com/ ↗ |
| Phone | 13026587581 |
| Employees | 334 |
| Revenue | $25.6M |
| Gross Profit | $21.4M |
| Net Income | -$7.8M |
| Free Cash Flow | -$25.1M |
| Total Assets | $94.6M |
| Total Liabilities | $85.5M |
| Equity | $9.1M |
About Biodesix Inc
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Biodesix Inc is a publicly traded company under the ticker symbol BDSX on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)